Malignant neoplasm of breast
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Assessing TBX3 by immunohistochemistry in early-stage (stage 0 and stage I) breast cancers revealed high expression in low-grade lesions.
|
30697731 |
2019 |
Malignant neoplasm of breast
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
TBX3 was associated with BC risk (rs2242442: OR = 0.76, 95% CI 0.64-0.92, dominant model) and with less aggressive tumour characteristics.
|
28238063 |
2017 |
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
In contrast, constitutive (MYC, TBX3) and signal-induced (TP53, FOXA1) DB-TFs that do not mediate default repression are directly altered in breast cancer.
|
28215225 |
2017 |
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
Our results suggest that restoration of miR-206 in Tbx3-positive breast cancer could be exploited for therapeutic benefit.
|
27100732 |
2016 |
Malignant neoplasm of breast
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Interestingly, aberrant TBX3 expression is associated with breast cancer and melanoma formation.
|
27632063 |
2016 |
Malignant neoplasm of breast
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Overall, these results indicate that TBX3 (isoform 1 or 2) expression can promote progression in a model of early breast cancer by altering cell properties involved in cell survival/colony formation and invasiveness, as well as key regulatory and EMT/invasiveness-related gene expressions.
|
27553211 |
2016 |
Malignant neoplasm of breast
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
RUNX1_rs8130963 (odds ratio (OR) = 2.25; 95 % CI 1.42-3.56; P = 0.0005; dominant model), TBX3_rs8853 (OR = 2.04; 95 % CI 1.38-3.01; P = 0.0003; dominant model), TBX3_rs1061651 (OR= 2.14; 95 % CI1.43-3.18; P = 0.0002; dominant model), TTN_rs12465459 (OR = 2.02; 95 % confidence interval 1.33-3.07; P = 0.0009; dominant model), were the most significantly associated SNPs with BC risk.
|
26920143 |
2016 |
Malignant neoplasm of breast
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
On MMU5, a QTL was detected (P = 8 × 10(-7)) that was syntenic to a human BrCa locus on h12q24.5 containing the genes Tbx3 and Tbx5.
|
25552398 |
2015 |
Malignant neoplasm of breast
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
TBX2 is preferentially amplified in BRCA1/2-associated breast cancers and TBX3 overexpression has been associated with advanced stage disease and estrogen-receptor-positive breast tumors.
|
23624936 |
2013 |
Malignant neoplasm of breast
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Increased levels of TBX3 have been shown to contribute to the oncogenic process, and TBX3 is overexpressed in several cancers, including breast cancer, liver cancer, and melanoma.
|
22535523 |
2012 |
Malignant neoplasm of breast
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
PMA-induced up-regulation of TBX3 is mediated by AP-1 and contributes to breast cancer cell migration.
|
20942798 |
2011 |
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
CTD_human |
Estrogen expands breast cancer stem-like cells through paracrine FGF/Tbx3 signaling.
|
21098263 |
2010 |
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
Endogenous TBX3 and HDACs interaction and colocalization are found in a breast cancer cell line by coimmunoprecipitation and immunofluorescence, respectively.
|
18245468 |
2008 |
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
In addition, TBX2, a homologue of TBX3, is active in preventing senescence in rodent cells and was found to be amplified in some human breast cancers, suggesting TBX3 plays a role in breast cancer.
|
15289316 |
2004 |
Malignant neoplasm of breast
|
0.600 |
CausalMutation
|
disease |
CGI |
|
|
|